title: [A case of postoperative hepatic metastasis from gastric cancer responding to hepatic arterial infusion chemotherapy of paclitaxel].
abstract: A 70-year-old man underwent total gastrectomy for advanced gastric cancer in January 2000. He was treated with UFT of 300 mg/day after surgery. In December 2000, liver metastasis was detected. In January 2001, treatment was switched to oral administration of TS-1 at 100 mg/day. In April 2001, there were no extrahepatic lesions. However, the metastatic liver focus showed progression of the disease (PD). TS-1 was discontinued. In May 2001, a hepatic arterial injection reservoir was inserted. Thereafter, arterial injection chemotherapy with 5-FU was administered. However, in November, liver dysfunction was exacerbated, and computed tomography (CT) revealed PD. Therefore, in December, the above chemotherapy was switched to arterial injection of paclitaxel at 100 mg, which was administered once a week for 3 weeks and discontinued for the subsequent week. In March 2002, hepatopathy had subsided at the end of the 4th course, the performance status (PS) improved and CT revealed a minor response. In June 2002, the condition deteriorated to PD. However, there were no side effects other than alopecia. During the administration period, treatment at the outpatient clinic could be safely performed. These findings suggest that hepatic arterial injection therapy with paclitaxel for liver metastasis after surgery for gastric cancer is a useful second line for 5-FU-resistant patients.
authors.affiliation: Dept. of Surgery, NTT West Osaka Hospital.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Matsui
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tono
authors.forename: Takashi
authors.initials: T
authors.lastname: Iwazawa
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Kinuta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yano
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nakano
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanoh
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Okada
authors.forename: Tadafumi
authors.initials: T
authors.lastname: Asaoka
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Imasato
authors.forename: Jun
authors.initials: J
authors.lastname: Okamura
authors.forename: Takushi
authors.initials: T
authors.lastname: Monden
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D017239:Paclitaxel; D005472:Fluorouracil